Lurasidone-d8 – 1 mg

Brand:
Cayman
CAS:
1132654-54-6
Storage:
-20
UN-No:
Non-Hazardous - /

Lurasidone-d8 is intended for use as an internal standard for the quantification of lurasidone (Item No. 9000570) by GC- or LC-MS. Lurasidone is an atypical antipsychotic that binds to dopamine D2, serotonin (5-HT) receptor subtypes 5-HT2A, 5-HT1A, and 5-HT7, and α2C-adrenergic receptors (Kis = 1.68, 2.03, 6.75, 0.495, and 10.8 nM, respectively).{42146} In vivo, pre-training administration of lurasidone (1 and 3 mg/kg) reverses impairment in step-through latency and passive avoidance in a foot shock test induced by MK-801 (Item No. 10009019) in rats. It reverses MK-801-induced learning impairment in the Morris water maze as well as reference and working memory impairment in the radial arm maze in rats.{42147} Lurasidone also decreases immobility in the tail suspension and forced swim tests, indicating antidepressant-like activity in mice.{42148} Formulations containing lurasidone have been used in the treatment of schizophrenia and mood disorders.  

 

Available on backorder

SKU: 25222 - 1 mg Category:

Description

An internal standard for the quantification of lurasidone by GC- or LC-MS


Formal name: (3aR,4S,7R,7aS)-2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl-2,2,3,3,5,5,6,6-d8]methyl]cyclohexyl]methyl]hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione

Synonyms: 

Molecular weight: 500.7

CAS: 1132654-54-6

Purity: ≥99% deuterated forms (d1-d8)

Formulation: A solid


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Receptor Pharmacology||Research Area|Neuroscience|Behavioral Neuroscience|Bipolar Disorder||Research Area|Neuroscience|Behavioral Neuroscience|Depression||Research Area|Neuroscience|Behavioral Neuroscience|Learning & Memory||Research Area|Neuroscience|Behavioral Neuroscience|Schizophrenia & Psychosis